Athens, Georgia — According to state and local economic development sources Boehringer Ingelheim plans to invest $55,000,000.00 to build out 63,000 square feet of new space in Athens. The company plans to occupy the new space at 1730 Olympic Drive in Athens, on or about April 1, 2024. According to the company website Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation. Boehringer Ingelheim is one of the worlds top 20 pharmaceutical companies. Headquartered in Ingelheim, Germany, the company operates globally with approximately 52,000 employees. Since its founding in 1885, the company has remained family-owned and today creates value through innovation for three business areas including human pharmaceuticals, animal health and biopharmaceutical contract manufacturing. The objectives and beliefs of Boehringer Ingelheim can be summed up in a single phrase: Value through Innovation. This vision has helped us build on our strengths and make the most of our distinctive character and corporate culture that is rooted in our belief that in order to be successful we must have a strong partnership with our people. Value through Innovation is what drives us to continuously search for new and innovative ways to improve the lives that we touch – whether that be lives of patients and their families, our employees or our community. Boehringer Ingelheim is also committed to providing valuable services and support to patients and their families.

To learn more about Boehringer Ingelheim, visit http://www.boehringer-ingelheim.us/

Company Contact:
Jean-Michel Boers, Chief Executive Officer
jean-michel.boers@boehringer-ingelheim.com
https://www.linkedin.com/in/jean-michel-boers-5b480b15/
800-325-9167

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved